Neurological illness following treatment with fludarabine
Open Access
- 1 November 1994
- journal article
- case report
- Published by Springer Nature in British Journal of Cancer
- Vol. 70 (5) , 966-968
- https://doi.org/10.1038/bjc.1994.430
Abstract
Fludarabine is a comparatively new drug for the treatment of low-grade lymphoid malignancy. This report describes five cases of unusual neurological illnesses occurring after treatment with fludarabine. These suggest that caution should be exercised in patients receiving fludarabine who develop neurological abnormalities, with prompt investigation and if necessary cessation of the drug.Keywords
This publication has 13 references indexed in Scilit:
- Long-term follow-up of patients with chronic lymphocytic leukemia treated with fludarabine as a single agent.1993
- Activity of fludarabine in previously treated non-Hodgkin's low-grade lymphoma: results of an Eastern Cooperative Oncology Group study.Journal of Clinical Oncology, 1992
- A loading dose/continuous infusion schedule of fludarabine phosphate in chronic lymphocytic leukemia.Journal of Clinical Oncology, 1991
- Fludarabine phosphate for the treatment of low grade lymphoid malignancyBritish Journal of Cancer, 1991
- Phase I clinical trials with fludarabine phosphate.1990
- CENTRAL-NERVOUS-SYSTEM TOXICITY WITH FLUDARABINE1986
- FLUDARABINE PHOSPHATE (NSC 312878) INFUSIONS FOR THE TREATMENT OF ACUTE-LEUKEMIA - PHASE-I AND NEUROPATHOLOGICAL STUDY1986
- CENTRAL-NERVOUS-SYSTEM TOXICITY OF FLUDARABINE PHOSPHATE1986
- Phase I and II study of fludarabine phosphate in leukemia: therapeutic efficacy with delayed central nervous system toxicity.Journal of Clinical Oncology, 1986
- Cerebrovascular "Moyamoya" DiseaseArchives of Neurology, 1969